1 – 50 of 152
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Precision Diagnostics in Myeloid Malignancies : Development and Validation of a National Capture-Based Gene Panel
(
- Contribution to journal › Article
-
Mark
Hairy cell leukemia variant and WHO classification correspondence Re : 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
2024) In Leukemia and Lymphoma(
- Contribution to journal › Article
-
Mark
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification
(
- Contribution to journal › Letter
-
Mark
Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications
(
- Contribution to journal › Article
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
-
Mark
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
(
- Contribution to journal › Article
- 2022
-
Mark
A risk score based on real-world data to predict early death in acute promyelocytic leukemia
(
- Contribution to journal › Article
-
Mark
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Regional differences in treatment and outcome for myeloma patients in Sweden : A population based Swedish myeloma register study
(
- Contribution to journal › Article
-
Mark
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia : Results from the HEAT-AML trial
(
- Contribution to journal › Article
- 2021
-
Mark
Combinatorial molecule screening identifies a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
(
- Contribution to journal › Article
-
Mark
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : The HOVON-SAKK-132 trial
(
- Contribution to journal › Article
-
Mark
Impact of treatment delay in acute myeloid leukemia revisited
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study
(
- Contribution to journal › Article
-
Mark
Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years
(
- Contribution to journal › Article
-
Mark
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
(
- Contribution to journal › Scientific review
-
Mark
Epidemiology and Etiology of AML
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Subcutaneous cladribine to treat multiple sclerosis : experience in 208 patients
(
- Contribution to journal › Article
- 2020
-
Mark
Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014 : improving performance status is a major contributing factor
(
- Contribution to journal › Letter
-
Mark
Clonal competition within complex evolutionary hierarchies shapes AML over time
(
- Contribution to journal › Article
-
Mark
Hypo, Hyper, or Combo : New paradigm for treatment of acute myeloid leukemia in older people
(
- Contribution to journal › Scientific review
-
Mark
Introducing patient-reported outcome in the acute leukemia quality registries in Sweden
(
- Contribution to journal › Article
-
Mark
Outcome and characteristics of non-measurable myeloma : A cohort study with population-based data from the Swedish Myeloma Registry
(
- Contribution to journal › Article
-
Mark
Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis
(
- Contribution to journal › Article
-
Mark
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting
(
- Contribution to journal › Article
-
Mark
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years
(
- Contribution to journal › Letter
- 2019
-
Mark
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting
(
- Contribution to journal › Article
-
Mark
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma
(
- Contribution to journal › Article
-
Mark
Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period
(
- Contribution to journal › Letter
-
Mark
Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia : A Pooled Analysis of Individual Patient Data From Nine International Cohorts
(
- Contribution to journal › Article
- 2018
-
Mark
Subpopulations of T regulatory cells in blood stem cell harvests influence development of acute graft versus host disease in allogeneic transplant recipients
(
- Contribution to journal › Article
-
Mark
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
(
- Contribution to journal › Article
-
Mark
A new genetic tool to improve immune-compromised mouse models : Derivation and CRISPR/Cas9-mediated targeting of NRG embryonic stem cell lines
(
- Contribution to journal › Article
-
Mark
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
(
- Contribution to journal › Article
-
Mark
Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry
(
- Contribution to journal › Article
-
Mark
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(Immuno)therapy
(
- Contribution to journal › Letter
-
Mark
Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow
(
- Contribution to journal › Letter
-
Mark
Acute myeloid leukemia in very old patients
(
- Contribution to journal › Article
- 2017
-
Mark
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
(
- Contribution to journal › Scientific review
-
Mark
Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia : A population-based study from the Swedish AML registry
(
- Contribution to journal › Article
-
Mark
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
(
- Contribution to journal › Article
-
Mark
Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden
(
- Contribution to journal › Letter
-
Mark
Early death rates remain high in high-risk APL : Update from the Swedish Acute Leukemia Registry 1997-2013
(
- Contribution to journal › Letter
-
Mark
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register
(
- Contribution to journal › Article
-
Mark
Chronic lymphocytic leukemia with mutated IGHV4-34 receptors : Shared and distinct immunogenetic features and clinical outcomes
(
- Contribution to journal › Article
-
Mark
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells
(
- Contribution to journal › Article
-
Mark
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
(
- Contribution to journal › Article